List view / Grid view
Lecanemab is the only approved Aβ monoclonal antibody that highly…
Lecanemab is the only approved Aβ monoclonal antibody that highly binds to and clears toxic protofibrils with high selectivity.
Part of Biogen’s prioritisation of its portfolio includes focusing on…
Part of Biogen’s prioritisation of its portfolio includes focusing on the advancement of its leading anti-amyloid beta Alzheimer’s treatment, LEQEMBI® (lecanemab-irmb).
The first approved oral treatment that provides rapid symptomatic improvement…
The first approved oral treatment that provides rapid symptomatic improvement in postpartum depression (PPD) is expected to be commercially available in the fourth quarter of 2023.
As part of its acquisition of Reata Pharmaceuticals, Biogen will…
As part of its acquisition of Reata Pharmaceuticals, Biogen will add the first US Food and Drug Administration (FDA)-approved treatment for Friedreich’s ataxia to its portfolio.
